Methenamine Hippurate Pfleger

Methenamine Hippurate, the active ingredient in Methenamine Hippurate Pfleger, is a urinary antiseptic presented as an oral formulation for oral use. It is employed to prevent recurrent urinary tract infections and to provide prophylaxis in patients with chronic urinary catheterization.

GNH USA supplies Methenamine Hippurate Pfleger as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets, and the company’s robust distribution network enables timely delivery to healthcare providers in Europe, Asia, Africa and the Americas.

Methenamine Hippurate is used in the urinary tract infection prophylaxis pathway to reduce bacterial colonisation.

- Recurrent urinary tract infections: helps prevent recurrence by maintaining sterile urine. - Chronic urinary catheterization: provides ongoing antimicrobial protection to reduce catheter‑associated infections. - Post‑operative catheter use: lowers the incidence of urinary infections following short‑term catheterisation. - Neurogenic bladder management: assists in preventing infections in patients with impaired bladder emptying.

Methenamine Hippurate may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea or upset stomach. - Vomiting or mild diarrhoea. - Dyspepsia or abdominal discomfort. - Skin rash or mild itching. - Headache or dizziness. - Urinary irritation or mild hematuria.

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Persistent or worsening renal impairment. - Significant hematuria unrelated to urinary irritation. - Acute liver injury (rare).

Before prescribing methenamine hippurate, clinicians should consider several safety aspects.

- Assess urine pH: ensure acidic environment for drug activation. - Monitor renal function: adjust or avoid in severe renal impairment. - Evaluate hepatic status: use caution in patients with liver disease. - Check for hypersensitivity: discontinue if allergic reactions occur. - Avoid concomitant alkalinizing agents: they may reduce efficacy. - Store at ambient temperature: keep in the original pack, protect from moisture.

Methenamine hippurate can interact with other medicines that alter urinary pH or renal handling.

Major Interactions (Avoid): - Alkalinizing agents (e.g., sodium bicarbonate): raise urine pH and markedly reduce drug activation. - Antacids containing magnesium or aluminum: increase urinary pH, diminishing antibacterial effect.

Moderate Interactions (Monitor Closely): - Loop diuretics: may concentrate urine and affect drug levels. - Nephrotoxic antibiotics (e.g., aminoglycosides): additive risk of kidney injury. - Warfarin: potential alteration of INR, requiring closer monitoring.